Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast Review uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Carcinoma, Intraductal, Noninfiltrating
  • Multicenter Studies as Topic
  • Radiotherapy, Adjuvant
  • Randomized Controlled Trials as Topic

abstract

  • Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. The proportional reduction in ipsilateral breast events was greater in older than in younger women (2P < .0004 for difference between proportional reductions; 10-year absolute risks: 18.5% vs 29.1% at ages <50 years, 10.8% vs 27.8% at ages ≥ 50 years) but did not differ significantly according to any other available factor. Even for women with negative margins and small low-grade tumors, the absolute reduction in the 10-year risk of ipsilateral breast events was 18.0% (SE 5.5, 12.1% vs 30.1%, 2P = .002). After 10 years of follow-up, there was, however, no significant effect on breast cancer mortality, mortality from causes other than breast cancer, or all-cause mortality.

authors

publication date

  • January 2010

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5161078

Digital Object Identifier (DOI)

  • 10.1093/jncimonographs/lgq039

PubMed ID

  • 20956824

Additional Document Info

start page

  • 162

end page

  • 77

volume

  • 41